Sponsor: PMV Pharmaceuticals, Inc.
Sponsor Study ID: PMV-586-101
Study Title: A Phase 1/2 Open label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
CTO #: 103704
NCT Number: NCT04585750
Phase: I/II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast, Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Ovary, Pancreas, Prostate, Soft Tissue, Stomach, Thyroid
Study Objectives: This study will assess the safety and tolerability of multiple dose levels of PC14586 in participants with advanced solid tumors containing a p53 Y220C mutation.